I. Gilloteau

1.3k total citations
48 papers, 998 citations indexed

About

I. Gilloteau is a scholar working on Immunology, Dermatology and Oncology. According to data from OpenAlex, I. Gilloteau has authored 48 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Immunology, 16 papers in Dermatology and 12 papers in Oncology. Recurrent topics in I. Gilloteau's work include Psoriasis: Treatment and Pathogenesis (29 papers), Dermatology and Skin Diseases (16 papers) and Spondyloarthritis Studies and Treatments (10 papers). I. Gilloteau is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (29 papers), Dermatology and Skin Diseases (16 papers) and Spondyloarthritis Studies and Treatments (10 papers). I. Gilloteau collaborates with scholars based in United States, Switzerland and Germany. I. Gilloteau's co-authors include Amir Goren, Marco DiBonaventura, Michael Lees, Matthias Augustin, Kristien Van der Elst, René Westhovens, Michelle Tran, Steven R. Feldman, Hongqing Tian and C. Papavassilis and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Annals of the Rheumatic Diseases.

In The Last Decade

I. Gilloteau

48 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Gilloteau United States 18 504 302 200 172 169 48 998
Vivian Herrera United States 16 341 0.7× 169 0.6× 72 0.4× 99 0.6× 260 1.5× 44 780
Erica D. Dommasch United States 14 647 1.3× 391 1.3× 52 0.3× 91 0.5× 229 1.4× 29 989
Ahmed M. Soliman United States 29 741 1.5× 236 0.8× 35 0.2× 89 0.5× 305 1.8× 142 2.9k
K Malottki United Kingdom 11 238 0.5× 99 0.3× 59 0.3× 124 0.7× 166 1.0× 17 725
Kathleen McElhone United Kingdom 21 1.3k 2.6× 572 1.9× 45 0.2× 237 1.4× 902 5.3× 39 1.9k
Liza Takiya United States 15 85 0.2× 137 0.5× 51 0.3× 86 0.5× 267 1.6× 47 888
Richard Shames United States 12 365 0.7× 176 0.6× 45 0.2× 14 0.1× 53 0.3× 20 911
Jessica Kubo United States 16 446 0.9× 58 0.2× 208 1.0× 17 0.1× 42 0.2× 24 1.2k
Brian Calimlim United States 19 136 0.3× 813 2.7× 35 0.2× 39 0.2× 228 1.3× 70 1.4k
Debra Kennedy Australia 18 129 0.3× 46 0.2× 72 0.4× 20 0.1× 94 0.6× 43 1.3k

Countries citing papers authored by I. Gilloteau

Since Specialization
Citations

This map shows the geographic impact of I. Gilloteau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Gilloteau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Gilloteau more than expected).

Fields of papers citing papers by I. Gilloteau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Gilloteau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Gilloteau. The network helps show where I. Gilloteau may publish in the future.

Co-authorship network of co-authors of I. Gilloteau

This figure shows the co-authorship network connecting the top 25 collaborators of I. Gilloteau. A scholar is included among the top collaborators of I. Gilloteau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Gilloteau. I. Gilloteau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cella, David, Patrick Y. Wen, Susan Vallow, et al.. (2023). Understanding the patient experience and treatment benefits in patients with non–small‐cell lung cancer with brain metastasis. Cancer Medicine. 12(12). 13637–13648. 2 indexed citations
2.
Strand, Vibeke, Gurjit S. Kaeley, Martin Bergman, et al.. (2022). The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. The Lancet Rheumatology. 4(3). e208–e219. 4 indexed citations
3.
Kvien, Tore K, Philip G. Conaghan, Laure Gossec, et al.. (2020). Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials. Arthritis Care & Research. 74(5). 759–767. 11 indexed citations
4.
Feldman, Steven R., et al.. (2019). Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. Journal of the American Academy of Dermatology. 80(6). 1650–1657. 22 indexed citations
5.
Igarashi, Atsuyuki, et al.. (2018). Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. Journal of Medical Economics. 22(1). 7–15. 6 indexed citations
6.
Warren, Richard B., et al.. (2018). Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. Journal of the European Academy of Dermatology and Venereology. 32(12). 2178–2184. 8 indexed citations
7.
Feldman, Steven R., Yang Zhao, I. Gilloteau, et al.. (2018). Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. Journal of Managed Care & Specialty Pharmacy. 24(7). 617–622. 18 indexed citations
8.
Poulos, Christine, Steven R. Feldman, I. Gilloteau, et al.. (2018). PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS’ TREATMENT CHOICE: A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US. Value in Health. 21. S434–S435. 1 indexed citations
9.
Fallowfield, Lesley, Eric Nadler, I. Gilloteau, et al.. (2017). Quality of survival: a new concept framework to assess the quality of prolonged life in cancer. Sussex Research Online (University of Sussex). 2(4). 225–232. 9 indexed citations
10.
Barbeau, M, et al.. (2017). Patient Characteristics and Disease Burden of Psoriasis In Mexico: A Real-World Physician and Patient Survey. Value in Health. 20(9). A808–A808. 1 indexed citations
11.
12.
Strober, Bruce, Alice B. Gottlieb, Bintu Sherif, et al.. (2017). Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology. 76(4). 655–661. 19 indexed citations
13.
14.
Colby, Chris, et al.. (2015). Predictors Of Utility Over Time Among Patients With Treatment-Naïve Advanced Melanoma From The Phase 3 Checkmate 066 Trial. Value in Health. 18(7). A474–A474. 7 indexed citations
15.
Long, Georgina V., Victoria Atkinson, Paolo A. Ascierto, et al.. (2015). Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066).. Journal of Clinical Oncology. 33(15_suppl). 9027–9027. 3 indexed citations
16.
Noens, Lucien, et al.. (2014). Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 99(3). 437–447. 65 indexed citations
17.
Benucci, Maurizio, Wiro B. Stam, I. Gilloteau, et al.. (2013). Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.. PubMed. 31(4). 575–83. 6 indexed citations
18.
Westhovens, René, et al.. (2013). Sleep Problems in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 41(1). 31–40. 89 indexed citations
19.
Goren, Amir, I. Gilloteau, J.R. Penrod, & Jacek Jassem. (2013). Assessing the Burden of Caregiving for Patients with Lung Cancer in Europe. Value in Health. 16(7). A403–A403. 1 indexed citations
20.
Mori, Asami, Amir Goren, I. Gilloteau, & Marco DiBonaventura. (2012). Quantifying the Burden of Caregiving for Patients with Cancer in Europe. Annals of Oncology. 23. ixe25–ixe26. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vivian Herrera Breakdown of academic impact, for papers by Erica D. Dommasch Breakdown of academic impact, for papers by Ahmed M. Soliman Breakdown of academic impact, for papers by K Malottki Breakdown of academic impact, for papers by Kathleen McElhone Breakdown of academic impact, for papers by Liza Takiya Breakdown of academic impact, for papers by Richard Shames Breakdown of academic impact, for papers by Jessica Kubo Breakdown of academic impact, for papers by Brian Calimlim Breakdown of academic impact, for papers by Debra Kennedy
Rankless by CCL
2026